Zydus gets Orphan Drug Designation from USFDA for ZYIL1 to treat Cryopyrin Associated Periodic… EP News Bureau Mar 21, 2023 Orphan drug designation by USFDA for ZYIL1 provides eligibility for certain development incentives, including tax credits for…
Zydus to begin phase-II (a) clinical trial of oral inflammasome inhibitor in patients with… EP News Bureau Dec 14, 2021 Cryopyrin-Associated Periodic Syndrome (CAPS) is a rare life-long auto-inflammatory condition, caused by NLRP3 activating…
